Success Metrics

Clinical Success Rate
81.0%

Based on 17 completed trials

Completion Rate
81%(17/21)
Active Trials
8(23%)
Results Posted
106%(18 trials)
Terminated
4(11%)

Phase Distribution

Ph phase_1
6
17%
Ph phase_2
18
51%
Ph phase_3
9
26%
Ph phase_4
2
6%

Phase Distribution

6

Early Stage

18

Mid Stage

11

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
6(17.1%)
Phase 2Efficacy & side effects
18(51.4%)
Phase 3Large-scale testing
9(25.7%)
Phase 4Post-market surveillance
2(5.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.3%

17 of 22 finished

Non-Completion Rate

22.7%

5 ended early

Currently Active

8

trials recruiting

Total Trials

35

all time

Status Distribution
Active(10)
Completed(17)
Terminated(5)
Other(3)

Detailed Status

Completed17
Recruiting8
Terminated4
Not yet recruiting2
unknown2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
35
Active
8
Success Rate
81.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (17.1%)
Phase 218 (51.4%)
Phase 39 (25.7%)
Phase 42 (5.7%)

Trials by Status

suspended13%
recruiting823%
withdrawn13%
not_yet_recruiting26%
completed1749%
terminated411%
unknown26%

Recent Activity

Clinical Trials (35)

Showing 20 of 35 trialsScroll for more
NCT03564340Phase 1

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recruiting
NCT06787612Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Recruiting
NCT07154290Phase 2

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT07484113Phase 1

IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

Not Yet Recruiting
NCT07286214Phase 4

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Not Yet Recruiting
NCT05428007Phase 2

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting
NCT04590326Phase 1

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Recruiting
NCT05535738Phase 2

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Recruiting
NCT03414502Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
NCT04324073Phase 2

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI

Completed
NCT03770273Phase 2

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Completed
NCT02776735Phase 2

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

Completed
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT04359901Phase 2

Sarilumab for Patients With Moderate COVID-19 Disease

Completed
NCT04008069Phase 2

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

Completed
NCT04134728Phase 3

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

Completed
NCT04842981Phase 1

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Terminated
NCT03449758Phase 4

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Completed
NCT02332590Phase 3

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

Completed
NCT04315298Phase 2

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Completed

Drug Details

Intervention Type
DRUG
Total Trials
35